What does the Lytenava (bevacizumab gamma) product information say about use during pregnancy?

Lytenava (bevacizumab gamma) has no available data in pregnant women and may pose a risk to human embryo-foetal development based on animal studies with other anti-VEGFs, so it should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus.